In a week marked by cautious Federal Reserve commentary and political uncertainty, global markets have experienced broad-based declines, with U.S. stocks facing significant challenges. Amid these turbulent conditions, investors often seek companies with strong growth potential and substantial insider ownership, as such characteristics can indicate confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Seojin SystemLtd (KOSDAQ:A178320) | 30.9% | 39.9% |
| People & Technology (KOSDAQ:A137400) | 16.4% | 37.3% |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.3% |
| SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
| Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
| On Holding (NYSE:ONON) | 19.1% | 29.4% |
| Pharma Mar (BME:PHM) | 11.8% | 56.2% |
| Fine M-TecLTD (KOSDAQ:A441270) | 17.2% | 131.1% |
| Credo Technology Group Holding (NasdaqGS:CRDO) | 13.4% | 66.3% |
| HANA Micron (KOSDAQ:A067310) | 18.5% | 110.9% |
Let's dive into some prime choices out of the screener.
NEXTIN (KOSDAQ:A348210)
Simply Wall St Growth Rating: ★★★★★★
Overview: NEXTIN, Inc. manufactures defect inspection and metrology systems for the semiconductor and display industries in South Korea, with a market cap of ₩549.91 billion.
Operations: The company's revenue segment for Semiconductor Equipment and Services amounts to ₩101.98 billion.
Insider Ownership: 12.1%
NEXTIN's earnings are forecast to grow significantly at 36.32% annually, surpassing the KR market rate. Revenue growth is also expected to outpace the market, projected at 29.8% per year. The company trades 22.1% below its estimated fair value with analysts predicting a potential price increase of 56.1%. Recent buybacks totaling KRW 4,991.89 million indicate strong insider confidence despite no significant insider trading activity in the past three months.
- Click here to discover the nuances of NEXTIN with our detailed analytical future growth report.
- Upon reviewing our latest valuation report, NEXTIN's share price might be too pessimistic.
Shenzhen Pagoda Industrial (Group) (SEHK:2411)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Shenzhen Pagoda Industrial (Group) Corporation Limited is a fruit retailer operating in China, Indonesia, Singapore, Hong Kong, and internationally with a market cap of HK$2.12 billion.
Operations: The company generates revenue through its trading segment, which accounts for CN¥1.15 billion, and its franchising segment, contributing CN¥9.88 billion.
Insider Ownership: 25.1%
Shenzhen Pagoda Industrial (Group) is poised for significant earnings growth at 37.9% annually, outpacing the Hong Kong market. Despite recent insider selling and volatile share prices, the company trades below industry averages with a P/E ratio of 10.5x compared to 18.5x. Revenue growth is forecasted at 15.2% per year, and recent share buybacks aim to enhance net asset value and earnings per share, reflecting strategic financial management amidst low profit margins of 1.8%.
- Dive into the specifics of Shenzhen Pagoda Industrial (Group) here with our thorough growth forecast report.
- Insights from our recent valuation report point to the potential undervaluation of Shenzhen Pagoda Industrial (Group) shares in the market.
Formycon (XTRA:FYB)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Formycon AG is a biotechnology company that develops biosimilar drugs in Germany and Switzerland, with a market cap of €926.99 million.
Operations: The company generates revenue from its Drug Delivery Systems segment, amounting to €60.80 million.
Insider Ownership: 14.2%
Formycon AG, recently added to the Germany SDAX Index, is positioned for substantial revenue growth at 32% annually, surpassing the German market. Despite past shareholder dilution and low future return on equity forecasts (13.4%), it offers strong earnings growth potential at 30.63% per year. Trading below industry averages with a P/E ratio of 14.5x, Formycon's strategic FDA approval of Otulfi enhances its biosimilar portfolio, supporting its competitive edge in biopharmaceuticals.
- Delve into the full analysis future growth report here for a deeper understanding of Formycon.
- Our valuation report here indicates Formycon may be undervalued.
Where To Now?
- Explore the 1512 names from our Fast Growing Companies With High Insider Ownership screener here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About XTRA:FYB
Formycon
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
High growth potential with excellent balance sheet.
